A recent study reveals that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise regimens.
Findings released in a major health publication demonstrates that while overweight individuals can lose a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Users purchasing these medications should be aware of the risk of fast weight regain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of recovery means a reversion to original mass in about a year and a half.
Weighing Therapies
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
The team note that people who lose weight through dieting usually have a more gradual weight regain—approximately 100 grams monthly—once they finish.
Explaining the Quick Rebound
Doctors propose the mode of action of the jabs explains the heightened regain.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone concentrations far above than normal might result in the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making overeating much more probable."
A Lifelong Issue?
Health authorities recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, considering the significant potential of weight regain, the treatment might need to be long-term.
This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the long-term character of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the medication explain a intense resurgence of hunger.
"I experienced a switch activating and I was suddenly extremely hungry," recalled a patient.
The struggle is exacerbated if users have not established permanent dietary or behavioural changes during treatment.
Significant Adoption
Survey data show that millions of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is higher among women than males.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while these medications are effective tools for weight loss, they are not a permanent fix and long-term success relies on ongoing behavioural support.
